Misset J L, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E
Service des Maladies Sanguines Immunitaires et Tumorales, Hôpital Paul Brousse, Villejuif, France.
Crit Rev Oncol Hematol. 2000 Aug;35(2):75-93. doi: 10.1016/s1040-8428(00)00070-6.
Oxaliplatin (Eloxatin), a recently developed third-generation cisplatin analogue with a 1,2-diaminocyclohexane (DACH) carrier ligand, has displayed preclinical and clinical activity in a wide variety of tumour types. Synergistic with 5-FU in colorectal cancer (CRC), the combination has proven efficacy in 5-FU-resistant advanced disease and in previously untreated CRC, as demonstrated in controlled phase III trials, while evaluation in the adjuvant setting is ongoing. Due to its excellent safety profile, its unique mechanism of action and lack of cross-resistance with other active agents in CRC, oxaliplatin has also been combined with CPT-11 and Raltitrexed with promising results. Trials in pretreated and untreated advanced ovarian cancer (AOC), as a single agent or in combination with cisplatin, cyclophosphamide or paclitaxel, indicate a yet to be defined role in AOC and confirm its lack of cross-resistance with cis/carboplatin. Clinical investigations of single agent and combination therapies in breast, lung, prostate and germ-cell carcinomas, non-Hodgkin's lymphoma and malignant mesothelioma are being pursued. While the role of oxaliplatin in medical oncology is yet to be fully defined, it appears to be an important new anticancer agent.
奥沙利铂（乐沙定）是一种最近开发的第三代顺铂类似物，带有1,2 - 二氨基环己烷（DACH）载体配体，已在多种肿瘤类型中展现出临床前和临床活性。在结直肠癌（CRC）中与5 - 氟尿嘧啶具有协同作用，如对照III期试验所示，该联合用药在5 - 氟尿嘧啶耐药的晚期疾病以及先前未治疗的结直肠癌中已证实有效，而辅助治疗环境中的评估正在进行。由于其出色的安全性、独特的作用机制以及与结直肠癌中其他活性药物不存在交叉耐药性，奥沙利铂还与伊立替康和雷替曲塞联合使用，取得了有前景的结果。在预处理和未治疗的晚期卵巢癌（AOC）中作为单药或与顺铂、环磷酰胺或紫杉醇联合使用的试验表明，其在AOC中的作用尚待确定，并证实其与顺铂/卡铂不存在交叉耐药性。正在开展关于奥沙利铂在乳腺癌、肺癌、前列腺癌和生殖细胞癌、非霍奇金淋巴瘤和恶性间皮瘤中的单药及联合治疗的临床研究。虽然奥沙利铂在医学肿瘤学中的作用尚未完全明确，但它似乎是一种重要的新型抗癌药物。
